Follow on Google News
News By Tag
News By Place
Follow on Google News
Coeptis Therapeutics Holdings, Inc to Collaborate with the University of Pittsburgh
to expand pre-clinical Development of SNAP-CAR T Cells Targeting HER2-Positive Cancers
By: SOURCE: CorporateAds.com
Focused on SNAP-CAR T Cells, a Platform Technology Being Developed to be Combined with Tagged, Tumor-Specific Antibodies to Potentially Target Many Different Tumor Types.
Research Agreement with the University of Pittsburgh to Expand Pre-Clinical Development of SNAP-CAR T Cells Targeting HER2-Positive Cancers.
Collaboration with IQVIA, a Global Contract Research Organization, to Identify Target Indications and Initiate IND-Enabling Activities.
CAR T Cell Therapy Market Expected to Reach $20.56 Billion by 2029 from $1.96 Billion in 2021.
Coeptis Therapeutics Holdings, Inc (https://coeptistx.com/)
Modified NK cells that are co-administered with select monoclonal antibodies and/or other CD38 targeting immunotherapies are in pre-clinical development to enhance and maximize tumor kill via combinatorial approaches otherwise not possible.
The COEP CD38 Diagnostic is designed to be used as a companion with CD38 GEAR-NK or as a standalone diagnostic screening test to determine which immunotherapies may be responsive to CD38+ tumors.
The COEP business model is designed around maximizing the value of its current product portfolio and rights through in-license agreements, out-license agreements and co-development relationships, as well as entering into strategic partnerships to expand its product rights and offerings, specifically those targeting cancer.
The CAR T cell therapy market size and share are expected to reach $20.56 billion by 2029 from $1.96 billion in 2021, at a compound annual growth rate (CAGR) of 31.6% during forecast period 2022 to 2029.1 1 (Source: Polaris Market Research).
Sponsored Research Agreement with the University of Pittsburgh to Advance SNAP-CAR Development Program
On January 31st COEP announced a sponsored research agreement with the University of Pittsburgh to advance pre-clinical development of SNAP-CAR T cells targeting HER2 as well as identify opportunities to expand the applicability of SNAP-CAR in oncology. SNAP-CAR, which COEP licensed from the University of Pittsburgh, is a multi-antigen chimeric antigen receptor T cell (CAR T)
DISCLAIMER: This article is purely for informational purposes and is not a recommendation in any way for buying or selling stocks
Dave Mehalick, President and CEO